Resources
Explore our range of resources which have been designed to support you in your management of patients.
What are you looking for?
top
This link will take you to the electronic medicines compendium (emc) website, which is a non-Novartis website.
Image
Image
JAKAVI® (ruxolitinib) is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. JAKAVI® is also indicated for adult patients with polycythaemia vera who are resistant to or intolerant of hydroxyurea.1
MF and PV educational modules
Understanding the disease burden of polycythaemia vera and the challenges of disease management
Polycythaemia vera (PV) is a myeloproliferative disorder that causes overproduction of red blood cells and is characterised by high symptom burden, risk of thrombotic events and disease transformation, and shortened life expectancy.2,3
This content is intended for UK healthcare professionals only and has been created and funded by Novartis Pharmaceuticals UK Ltd.
PV CPD-accredited modules
Take these short modules to learn about the range of symptoms experienced by patients with PV, the diagnostic process, the signs of disease progression and the treatment options available.
A certificate will be available to download upon completion of each module.
Image
Module 1
The symptom burden, complications and prognosis of polycythaemia vera
In this module you will gain an increased awareness of the diagnostic criteria for PV as well as the range of symptoms experienced by patients and the risk of disease progression.
Image
Module 2
Timely management of polycythaemia vera: considerations and pitfalls
Complete this module to learn more about the different treatment options available for PV and their limitations, and understand the risks associated with insufficient control of PV.
Image
Module 3
The treatment landscape for polycythaemia vera
Increase your knowledge on first-, second- and later-line treatment options for PV, view risk: benefit considerations and read BSH guideline recommendations for high-risk patients.
By clicking on the links above, you will be directed to Novartis promotional webpages.
Understanding the symptoms of myelofibrosis and individual patient needs
Myelofibrosis (MF) is a progressive and debilitating disease.1 Patients have a considerably shortened life expectancy and experience substantial morbidity, including burdensome symptoms that affect their quality of life.4–7 MF is a heterogeneous disease, influenced by the genetic profile of the patient.7
Identifying genetic mutations, stratifying risk and monitoring symptom burden can help optimise treatment for each individual patient, according to their need.1, 8–12
This content is intended for UK healthcare professionals only and has been created and funded by Novartis Pharmaceuticals UK Ltd.
The INGRAIN-MF programme
Incorporating genetics, risk and associated burden into MF management
The INGRAIN-MF programme consists of four, short, CPD-accredited modules, designed to increase your awareness and understanding of the factors that influence disease manifestation and progression in MF, and the implications for managing and treating individual patients.
A certificate will be available to download upon completion of each module.
Image
Module 1
The burden of Myelofibrosis
In this module, you will learn about survival and transformation rates in MF; diagnostic criteria and clinical features; the symptom burden on patients and the objective monitoring of symptoms.
Image
Module 2
The influence of genetic factors in Myelofibrosis
Learn about mutations in MF; the importance of genetic information in diagnosis; how a patient’s molecular profile affects their prognosis and the potential of next-gen sequencing.
Image
Module 3
A personalised approach to predicting prognosis in Myelofibrosis
In this module, you will learn about clinical, demographic, cytogenetic and genetic risk factors; different prognostic scoring systems; as well as the use and implications of risk stratification.
Image
Module 4
Optimising management of Myelofibrosis and investigating the use of JAK inhibitors
Learn about different treatment options for MF; the efficacy and tolerability profiles of JAK inhibitors in controlling MF‑related symptoms; and considerations for the use of ruxolitinib.
By clicking on the links above, you will be directed to Novartis promotional webpages.
BSH, British Society for Haematology; PV, polycythaemia vera.
References
JAKAVI® (ruxolitinib) Summary of Product Characteristics.
Teeri A, et al. Leukemia 2021;35(12):3339–3351.
Harrison CN, et al. Ann Hematol 2017;96(10):1653–1665.
Zahr AA, et al. Haematologica 2016;101(6):660–671.
Harrison CN, et al. Ann Hematol 2017;96(10):1653–1665.
Brunner AM, et al. Leuk Lymphoma 2016;57(5):1197–1200.
Rumi E, et al. Blood 2014;124(7):1062–1069.
Knight EA, et al. J Adv Pract Oncol 2015;6(6):532–550.
Cervantes F, et al. Blood 2009;113(13):2895–2901.
Loscocco GG, et al. Onco Targets Ther 2020;13:12367–12382.
National Institute for Health and Care Excellence. Technology appraisal guidance 386. Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis, March 2016 (last reviewed July 2019). Available at: https://www.nice.org.uk/guidance/ta386/resources/ruxolitinib-for-treating-diseaserelated-splenomegaly-or-symptoms-in-adults-with-myelofibrosis-pdf-82602853065925 [Accessed September 2025].
Kröger NM, et al. Leukemia 2015;29(11):2126–2133.
UK | November 2025 | FA-11208708-2
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email [email protected] or call 01276 698370.
Welcome to Pro.Novartis.com
The Novartis portal for UK healthcare professionals (HCPs) and other relevant decision makers* is where you can find promotional information about Novartis products, therapy area materials and professional resources.
*Other relevant decision makers particularly includes those with an NHS role who could influence in any way the administration, consumption, prescription, purchase, recommendation, sale, supply or use of any medicine but who are not health professionals.
This website is designed to be viewed on desktop.
Welcome to Pro.Novartis.com
The Novartis portal for UK healthcare professionals (HCPs) and other relevant decision makers* is where you can find promotional information about Novartis products, therapy area materials and professional resources.
*Other relevant decision makers particularly includes those with an NHS role who could influence in any way the administration, consumption, prescription, purchase, recommendation, sale, supply or use of any medicine but who are not health professionals.
This website is designed to be viewed on desktop.